Real-world clinical study of artificial intelligence-based precision albumin therapy for critically ill patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300069558

Enrollment

Unknown

Registered

2023-03-20

Start date

2023-03-24

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoproteinemia

Interventions

Group of hypoproteinemia:None

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. critically ill and trauma patients who have been discussed by senior physicians as requiring albumin infusion. 2. adult patients older than 18 years of age. 3. trauma patients: ISS = 16 or AIS = 4 or GCS = 8. 4. APACHE II score = 12 on the day of admission to the emergency intensive care unit. *Criteria 3 and 4 can satisfy one

Exclusion criteria

Exclusion criteria: 1. Cachexia stage III 2. patient or family refusal of albumin infusion. 3. female patient during pregnancy or lactation. 4. patients on continuous renal replacement therapy (CRRT), ultrafiltration therapy, extracorporeal membrane lung combination therapy (ECMO) patients during data collection. 5. patients enrolled in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Serum albumin concentration;	—

Countries

China

Contacts

Public ContactLi Chang

Sichuan Provincial People`s Hospital

932516443@qq.com+86 18981838126

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026